Edition:
India

Bioverativ Inc (BIVV.OQ)

BIVV.OQ on NASDAQ Stock Exchange Global Select Market

56.11USD
17 Nov 2017
Change (% chg)

$0.82 (+1.48%)
Prev Close
$55.29
Open
$54.99
Day's High
$56.19
Day's Low
$54.98
Volume
287,774
Avg. Vol
368,349
52-wk High
$64.40
52-wk Low
$41.21

Select another date:

Fri, Oct 27 2017

BRIEF-Bioverativ reports Q3 earnings per share $0.63

* Q3 revenue $291.6 million versus i/b/e/s view $285.5 million

BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400

* Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia

BRIEF-Bioverativ and Bicycle Therapeutics enter into strategic research collaboration

* Bioverativ and Bicycle Therapeutics enter into strategic research collaboration to develop therapies for haemophilia and sickle cell disease

BRIEF-Bioverativ reports Q2 GAAP earnings per share $0.71

* Q2 earnings per share view $0.71 -- Thomson Reuters I/B/E/S

BRIEF-Valueact Capital Management LLC reports 3.8 pct stake in Bioverativ Inc as of July 13 - SEC filing

* Valueact Capital Management LLC reports 3.8 percent stake in Bioverativ Inc as of July 13 versus 7.5 percent stake as of Feb 28 - SEC filing Source text:(http://bit.ly/2u29MGC) Further company coverage:

BRIEF-Bioverativ says on June 28, entered into a credit agreement

* Bioverativ inc - on june 28, entered into a credit agreement by and among bioverativ and certain subsidiaries as borrowers - sec filing

BRIEF-Amunix Operating Inc says FDA has accepted Bioverativ's IND application for BIVV001

* Bioverativ announces FDA acceptance of investigational new drug application for BIVV001, a novel, long-acting FVIII hemophilia therapeutic utilizing amunix XTEN® half-life extension technology

BRIEF-Bioverativ announces FDA acceptance of investigational new drug application for BIVV001

* Bioverativ announces FDA acceptance of investigational new drug application for BIVV001 to treat hemophilia A

BRIEF-HBM Healthcare Investments: Bioverativ acquires HBM-portfolio company True North Therapeutics

* BIOVERATIV ACQUIRES HBM-PORTFOLIO COMPANY TRUE NORTH THERAPEUTICS FOR UP TO USD 825 MILLION PLUS ASSUMED CASH Source text - http://bit.ly/2qgeVHB Further company coverage: (Gdynia Newsroom)

BRIEF-Bioverativ to acquire True North Therapeutics

* Bioverativ to acquire clinical-stage rare disease biotechnology company, True North Therapeutics

Select another date: